Lensar develops and manufactures Femtosecond Lasers Systems designed specifically for refractive cataract surgery, Irvine, Calif.-based Alphaeon said.
“We are pleased to have closed the acquisition of Lensar. The advancements they have made in the self-pay category of precision refractive surgery complement our lifestyle product portfolio, allowing ophthalmologists to offer another alternative to patients,” Alphaeon CEO Robert Grant said in prepared remarks.
The purchase was originally announced in November. Orlando, Fl.-based Lensar said the $59 million transaction would be paid in cash, stock and assumed debt, and hoped it would close before December 31.
The $59 million transaction will be paid in cash, stock and assumed debt and is expected to close on or before Dec. 31 this year, Orlando, Fl.-based Lensar said.
“The opportunity to partner with Alphaeon furthers Lensar’s commitment to provide ophthalmologists everywhere with the latest developments in premium vision surgery. We’re excited with the chance to join Alphaeon, and together leverage our proprietary platform technology to develop new clinical innovations benefiting physicians and patients alike,” Lensar CEO Nick Curtis said in prepared remarks.
Last October, Lansar lured Hansen Medical‘s Peter Mariani to take over as it’s CFO, and added an ex-Orthofix (NSDQ:OFIX) CEO and an NxThera CFO to board.